ALK CLTC-ALK

T（2；17）（p23；q23）易位导致CLTC-ALK融合蛋白，这是弥漫性大B细胞淋巴瘤（dlbcl）中最常见的ALK融合蛋白。ALK重排DLBCL对CHOP化疗的反应较低。临床前研究表明，在细胞系和小鼠模型中，CLTC-ALK-DLBCL对ALK抑制有反应，两个病例研究表明，当重度预处理和晚期ALK阳性的DLBCL用环唑替尼治疗时，反应短暂，随后进展（一例为CLTC-ALK，一例为未知的ALK融合）。
The t(2;17)(p23;q23) translocation results in the CLTC-ALK fusion protein, the most common ALK fusion observed in diffuse large B cell lymphoma (DLBCL). ALK-rearranged DLBCL is less responsive to CHOP chemotherapy. Preclinical work indicates that CLTC-ALK DLBCL is responsive to ALK inhibition in cell lines and mouse models, and two case studies show short response followed by progression when heavily pretreated and advanced ALK-positive DLBCL is treated with crizotinib (one case CLTC-ALK, one case an unknown ALK fusion).